Jane Street Group, LLC Adverum Biotechnologies, Inc. Call Options Transaction History

Jane Street Group, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 17, 2022	SELL	$1.23 - $1.95 $101,475 - $160,875	-82,500 Closed	0 $0
Q4 2021 Feb 15, 2022	SELL	$1.74 - $2.4 $139,374 - $192,240	-80,100 Reduced 49.26%	82,500 $145,000
Q3 2021 Nov 16, 2021	SELL	$2.08 - $3.6 $882,544 - $1.53 Million	-424,300 Reduced 72.3%	162,600 $353,000
Q2 2021 Aug 16, 2021	BUY	$3.36 - $10.56 $1.86 Million - $5.84 Million	552,900 Added 1626.18%	586,900 $2.05 Million
Q4 2020 Feb 17, 2021	BUY	$9.84 - $14.26 $31,488 - $45,632	3,200 Added 10.39%	34,000 $369,000
Q3 2020 Nov 17, 2020	SELL	$10.3 - $21.64 $610,790 - $1.28 Million	-59,300 Reduced 65.82%	30,800 $317,000
Q2 2020 Aug 17, 2020	BUY	$8.53 - $25.64 $768,553 - $2.31 Million	90,100 New	90,100 $1.88 Million

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.